Heart failure is a syndrome that results from the inability of the cardiac pump to function properly to ensure the metabolic demand of the body. Its affects more than 60 million of patients worldwide and is the only cardiac disease that continues to grow, despite standard of care, accross various HF subpopulations.


The clinical course of heart failure (HF) is characterized by periods of clinical stability frequently interrupted by episodes of worsening symptoms and signs defined as Worsening heart failure (WHF). Given the pivotal role of congestion in WHF, loop diuretics are a cornerstone of its therapy.

Although effective acutely, loop diuretics do not provide long-term benefits on rehospitalization rates. Therefore, WHF remains a critically important unmet medical need that continues to have a major impact on quality of life and imposes a major economic burden on the global health care system. The multi-organ activity of CRF2 agonist offers a great opportunity for treating WHF by insuring a complete and sustained decongestion while improving the cardiovascular and renal functions.